Aegis Thinks Its Okay To Buy IGXT, IntelGenx Technologies

Although they have no independent ability to conduct clinical studies or manufacture their own products, IntelGenx Technologies Corp. (IGXT) is a “buy“. Wall Street analysts at Aegis initiated coverage on the drug delivery company and gave IGXT stock a $2.50 price target, nearly 5 times the current price of the penny stock, 0.531. An bold move by the experts for a Company that is ...

Continue Reading →